Sign inJoin waitlistJoin the waitlist

Naval Daver

Director, Leukemia Research Alliance Program · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Leukemia Research Alliance Program · University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
Baylor College of Medicine
2008–2011
Internal Medicine
Baylor College of Medicine
2005–2008
Baylor College of Medicine
2004–2005
Doctor of Medicine
2000–2004

Research

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Review · Leukemia · 2019 · First of 4 authors · 869 citations
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Nature Medicine · 2018 · 800 citations

Hagop Kantarjian
373 papers
Tapan Kadia
350 papers
Courtney DiNardo
303 papers
Guillermo Garcia-Manero
302 papers
Elias Jabbour
284 papers
GB
Gautam Borthakur
267 papers
Marina Konopleva
227 papers
Naveen Pemmaraju
224 papers
Nicholas Short
198 papers · 12 as a fellow
Jorge Cortes
152 papers
KS
Koji Sasaki
152 papers · 20 as a resident
Ghayas Issa
127 papers · 5 as a fellow

Clinical trials

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2021–2023
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020–2025
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1, Phase 2
Aptose Biosciences Inc.
2019–2027
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2019–2023